Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Oncology

• Publication date

  2004-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDH280PMID 15205206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flt-3 Ligand and Sequential FL/Interleukin-2 in Patients With Metastatic Renal Carcinoma: Clinical and Biologic Activity

  2002cited by this paper
• Interleukin-2 in the treatment of renal cancer.

  2000cited by this paper
• B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion

  2000cited by this paper
• The Emerging Role of Cytokines in the Treatment of Advanced Melanoma

  2000cited by this paper
• Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.

  1999cited by this paper
• B cells inhibit induction of T cell-dependent tumor immunity

  1998cited by this paper
• Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

  1998cited by this paper
• B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses.

  1998cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

  1997cited by this paper
• Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.

  1997cited by this paper
• Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.

  1995cited by this paper
• Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

  1994cited by this paper
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• CD4+ AND B LYMPHOCYTES IN TRANSPLANTATION IMMUNITY: II. AUGMENTED REJECTION OF TUMOR ALLOGRAFTS BY MICE LACKING B CELLS

  1993cited by this paper
• Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.

  1991cited by this paper
• Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

  1985cited by this paper
• Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

  1985cited by this paper
• Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor.

  1978cited by this paper
• EVIDENCE OF SUPPRESSOR CELL ACTIVITY IN SPLEENS OF MICE BEARING PRIMARY TUMORS INDUCED BY MOLONEY SARCOMA VIRUS

  1974cited by this paper

• B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity.

  2026cites this paper
• The Multifaceted Roles of Tumor-Infiltrating Plasma Cells in Cancer Immunology

  2025cites this paper
• The role of B cell immunity in lung adenocarcinoma

  2025cites this paper
• Immune Microenvironment in Breast Cancer Metastasis.

  2025cites this paper
• PPARδ inhibition blocks the induction and function of tumor-induced IL-10+ regulatory B cells and enhances cancer immunotherapy

  2023cites this paper
• Neglected no more: B cell-mediated anti-tumor immunity.

  2022cites this paper
• B cell receptor signaling strength modulates cancer immunity

  2022cites this paper
• B cells in pancreatic cancer stroma

  2022cites this paper
• Mechanisms of induction of regulatory B cells in the tumour microenvironment and their contribution to immunosuppression and pro-tumour responses

  2022cites this paper
• Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity

  2022cites this paper
• Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial

  2021cites this paper
• Mathematical modeling of tumor-immune system interactions: the effect of rituximab on breast cancer immune response.

  2021cites this paper
• Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance

  2021cites this paper
• Regulatory B cells in cancer

  2020cites this paper
• B cells, plasma cells and antibody repertoires in the tumour microenvironment

  2020cites this paper
• Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity.

  2020cites this paper
• Humoral immune responses: Unsung heroes of the war on cancer.

  2020cites this paper
• Sustained complete remission of metastatic melanoma on targeted therapy and rituximab for rheumatoid arthritis

  2019cites this paper
• The B-Side of Cancer Immunity: The Underrated Tune

  2019cites this paper
• Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

  2018cites this paper
• Rituximab as a therapeutic option for patients with advanced melanoma

  2018cites this paper
• Clinical Relevance of Immune Cells in Pancreatic Adenocarcinoma and their Implication in Immunotherapy

  2018cites this paper
• A Paradoxical Correlation of Cancer-Associated Fibroblasts With Survival Outcomes in B-Cell Lymphomas and Carcinomas

  2018cites this paper
• Title : Antigen-presenting intratumoral B cells affect CD 4 + TIL phenotypes in non-small cell lung cancer patients

  2017cites this paper
• B cell regulation in cancer and anti-tumor immunity

  2017cites this paper
• Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non–Small Cell Lung Cancer Patients

  2017cites this paper
• The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities

  2017cites this paper
• B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment

  2017cites this paper
• Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma

  2016cites this paper
• B lymphocytes and cancer: a love-hate relationship.

  2016cites this paper
• CD19+CD20−CD27hi IL‐s10‐producing B cells are overrepresented in R‐CHOP‐treated DLBCL patients in complete remission

  2016cites this paper
• Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma

  2016cites this paper
• Tertiary lymphoid tissue in colorectal cancer : a key player in the tumour immune microenvironment

  2016cites this paper
• B Cells and Regulatory B Cells in Cancer Escape

  2016cites this paper
• B cell regulation of the anti-tumor response and role in carcinogenesis

  2016cites this paper
• Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models

  2016cites this paper
• Collaboration between tumor-specific CD4+ T cells and B cells in anti-cancer immunity

  2016cites this paper
• Regulatory B cells in anti-tumor immunity.

  2015cites this paper
• A Genomic Approach to the Identity, Clonal Diversity, and Clinical Import of Tumor-infiltrating Lymphocytes in Human Cancers

  2015cites this paper
• Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?

  2014cites this paper
• Difficulties in Targeting the Beating Heart

  2014cites this paper
• Inhibition of Breast Cancer Metastasis by Resveratrol-Mediated Inactivation of Tumor-Evoked Regulatory B Cells

  2013cites this paper
• Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.

  2013cites this paper
• B cells and their mediators as targets for therapy in solid tumors.

  2013cites this paper
• B cell-regulated immune responses in tumor models and cancer patients

  2013cites this paper
• Melanoma and Rituximab: An Incidental Association?

  2013cites this paper
• Tumor-Evoked Regulatory B Cells as Important Mediators of Cancer Escape

  2013cites this paper
• Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses.

  2012cites this paper
• A New Paradigm for an Old Story: The Role of Regulatory B Cells in Cancer

  2012cites this paper
• Eradication of melanomas by targeted elimination of a minor subset of tumor cells

  2011cites this paper
• The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth

  2011cites this paper
• The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model

  2011cites this paper
• B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models

  2008cites this paper
• Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma

  2007cites this paper
• Vaccines to treat cancer‐an old approach whose time has arrived

  2007cites this paper
• Immune resistance orchestrated by the tumor microenvironment

  2006cites this paper
• Rituximab: Applications in dermatology

  2006cites this paper
• Immune suppression in the tumor microenvironment.

  2006cites this paper
• Inhibitory effects of B cells on antitumor immunity.

  2006cites this paper
• Head and Neck

  2005cites this paper